Onco-Cardiology: Consensus Paper of the German Cardiac Society, the German Society for Pediatric Cardiology and Congenital Heart Defects and the German Society for Hematology and Medical Oncology
Tienush Rassaf, Matthias Totzeck, Johannes Backs, Carsten Bokemeyer, Michael Hallek, Denise Hilfiker‐Kleiner, Andreas Hochhaus, Diana Lüftner, Oliver J. Müller, Ulrich Neudorf, Roman Pfister, Stephan von Haehling, Lorenz Lehmann, Johann Bauersachs
Abstract
The acute and long-lasting side effects of modern multimodal tumour therapy significantly impair quality of life and survival of patients afflicted with malignancies. The key components of this therapy include radiotherapy, conventional chemotherapy, immunotherapy and targeted therapies. In addition to established tumour therapy strategies, up to 30 new therapies are approved each year with only incompletely characterised side effects. This consensus paper discusses the risk factors that contribute to the development of a potentially adverse reaction to tumour therapy and, in addition, defines specific side effect profiles for different treatment groups. The focus is on novel therapeutics and recommendations for the surveillance and treatment of specific patient groups.